Assessments of Neoadjuvant Hormone Therapy Followed by Robotic-Assisted Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer

It is still unclear whether neoadjuvant hormone therapy (NHT) followed by radical prostatectomy is the best treatment option for advanced prostate cancer. This study aimed to evaluate the benefits of NHT followed by robotic-assisted laparoscopic radical prostatectomy (RaLP) in locally advanced prost...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2017-06, Vol.37 (6), p.3143
Main Authors: Hu, Ju-Chuan, Hung, Sheng-Chun, Ou, Yen-Chuan
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents, Hormonal - adverse effects
Antineoplastic Agents, Hormonal - therapeutic use
Blood Loss, Surgical
Chemotherapy, Adjuvant
Disease-Free Survival
Humans
Kallikreins - blood
Kaplan-Meier Estimate
Laparoscopy - adverse effects
Male
Margins of Excision
Middle Aged
Neoadjuvant Therapy - adverse effects
Operative Time
Patient Selection
Proportional Hazards Models
Prostate-Specific Antigen - blood
Prostatectomy - adverse effects
Prostatectomy - methods
Prostatic Neoplasms - blood
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Recurrence
Retrospective Studies
Risk Factors
Robotic Surgical Procedures - adverse effects
Time Factors
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It is still unclear whether neoadjuvant hormone therapy (NHT) followed by radical prostatectomy is the best treatment option for advanced prostate cancer. This study aimed to evaluate the benefits of NHT followed by robotic-assisted laparoscopic radical prostatectomy (RaLP) in locally advanced prostate cancer. This study included 48 patients that had received NHT prior to RaLP by a single surgeon. The control group was selected using computerized 1:1 ratio matching. General characteristics, peri-operative parameters, and oncologic outcomes were analyzed retrospectively. Significantly shorter operative time, lesser blood loss and lower positive surgical margins were reported in the NHT group. The median period to biochemical recurrence (BCR) was shorter (3 months vs. 5 months, p=0.0145) and the overall BCR rate was lower (54.17% vs. 87.5%, p=0.0243). NHT followed by RaLP may provide clinicopathological benefits, especially in patients with pre-operative PSA values between 10-20 and above 50. Further prospective studies are needed to assess the impacts of NHT.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.11672